Keros Therapeutics Inc [KROS] stock prices are up 9.78% to $62.28 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KROS shares have gain 10.07% over the last week, with a monthly amount glided 3.90%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $96 on September 23, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $102 as its price target on June 25, 2024. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $60 on this stock.
The stock price of Keros Therapeutics Inc [KROS] has been fluctuating between $27.31 and $73.00 over the past year. Currently, Wall Street analysts expect the stock to reach $102.6 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $62.28 at the most recent close of the market. An investor can expect a potential return of 64.74% based on the average KROS price forecast.
Analyzing the KROS fundamentals
The Keros Therapeutics Inc [NASDAQ:KROS] reported sales of 0.65M for trailing twelve months, representing a surge of 4750.00%. Gross Profit Margin for this corporation currently stands at -0.27% with Operating Profit Margin at -313.42%, Pretax Profit Margin comes in at -278.91%, and Net Profit Margin reading is -278.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.42 and Total Capital is -0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 58.47 points at the first support level, and at 54.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 64.25, and for the 2nd resistance point, it is at 66.23.
Ratios To Look Out For
It’s worth pointing out that Keros Therapeutics Inc [NASDAQ:KROS]’s Current Ratio is 19.03. Also, the Quick Ratio is 19.03, while the Cash Ratio stands at 18.3. Considering the valuation of this stock, the price to sales ratio is 3881.24, the price to book ratio is 4.59.
Transactions by insiders
Recent insider trading involved GORDON CARL L, Director, that happened on Aug 13 ’24 when 0.25 million shares were sold. Director, ORBIMED ADVISORS LLC completed a deal on Aug 13 ’24 to sell 0.25 million shares. Meanwhile, Shareholder OrbiMed Genesis Master Fund, L bought 29400.0 shares on Aug 13 ’24.
